Alexander M.M. Eggermont

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

As adjuvant therapy for high-risk stage III melanoma, 200 mg of pembrolizumab administered every 3 weeks for up to 1 year resulted in significantly longer recurrence-free surviv...

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation. (Funded by Hoffmann-La ...

Final Version of 2009 AJCC Melanoma Staging and Classification

Purpose To revise the staging system for cutaneous melanoma on the basis of data from an expanded American Joint Committee on Cancer (AJCC) Melanoma Staging Database. Methods Th...